Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEZ235 in Advanced Renal Cell Carcinoma
NCT01453595Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2011
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dactolisib in renal cell carcinoma (RCC), sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2011; status: terminated.
02
Drugs
dactolisib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01453595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01453595.